DavidPeterCosgroveMD

Oncology • Vancouver, WA

Medical Oncologist, Sidney Kimmel Comprehensive Cancer Center

Join to view full profile

Dr. Cosgrove is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cosgrove's full profile

Already have an account?

Office
210 SE 136th Ave
Vancouver, WA 98684
Phone+1 360-944-9889

Fax+1 360-944-9686

Summary

Dr. Cosgrove specializes in general adult oncology with advanced subspecialty expertise in breast and gastrointestinal (GI) cancers. He is a strong advocate for bringing leading edge therapies to his patients through clinical trials. He serves on The US Oncology Research Network’s national GI Research Committee and as a principal investigator for many studies.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2006 - 2009
Johns Hopkins UniversityResidency, Internal Medicine, 2003 - 2006
University College of Dublin National Univ SOMClass of 2000

Certifications & Licensure

OR State Medical License 2015 - 2025
WA State Medical License 2015 - 2025
MD State Medical License 2006 - 2016

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer Start of enrollment: 2012 Jan 01
Completed
Phase 1, Phase 2
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy Start of enrollment: 2011 Jul 01
Completed
Phase 3
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) Start of enrollment: 2012 Jul 12
Completed
Phase 2
Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma Start of enrollment: 2013 Jan 01
Active, not recruiting
Phase 2
Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma Start of enrollment: 2014 Feb 01
Completed
Phase 2
Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer Start of enrollment: 2014 Feb 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

135 citations
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.
Edward A. Sausville, Patricia LoRusso, Michael A. Carducci, Judith Carter, Mary F. Quinn
Cancer Chemotherapy and Pharmacology. 2014-01-22
368 citations
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.
Eric A. Klein, Donald A. Richards, Allen Lee Cohn, M.K. Tummala, Rosanna Lapham
Annals of Oncology. 2021-09-01
124 citations
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells
Hiroyuki Konishi, Morassa Mohseni, Akina Tamaki, Joseph P. Garay, Sarah Croessmann
Proceedings of the National Academy of Sciences of the United States of America. 2011-10-25

Other Languages

German

External Links

Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/david-cosgrove